Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial

(2009) C Bengala et al.   BRITISH JOURNAL OF CANCER

gp130-Mediated Stat3 Activation in Enterocytes Regulates Cell Survival and Cell-Cycle Progression during Colitis-Associated Tumorigenesis

(2009) Julia Bollrath et al.   CANCER CELL

IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer

(2009) Sergei Grivennikov et al.   CANCER CELL

Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2

(2009) Boris R. A. Blechacz et al.   HEPATOLOGY

Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment

(2008) Boris Blechacz et al.   HEPATOLOGY

Potentin vitroandin vivoantitumor activity of interleukin-4-conjugatedPseudomonasexotoxin against human biliary tract carcinoma

(2008) Kazunori Ishige et al.   INTERNATIONAL JOURNAL OF CANCER

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE